Gyre Therapeutics amends 8-K to correct Cullgen stock conversion terms in $300M acquisition

GYRE THERAPEUTICS, INC.

Amendment fixes clerical error in original March 2, 2026 8-K describing stock conversion for Cullgen holders.
Designated Cullgen shareholders receive Series B Convertible Preferred, convertible into 5 Gyre common shares each.
Other Cullgen holders receive Gyre common stock at exchange ratio of 0.4753 per Cullgen share.
All-stock deal values Cullgen at ~$300 million; no substantive changes to merger agreement beyond correction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.